Public IDs No public external ID is attached.
Related people No reviewed person affiliation is attached.
Outputs No reviewed output is linked through affiliated people.
Relationship evidence A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers (NCT07545122)
PRODUCED BY incoming 82% confidence
Timeline No dated relationship evidence is attached.
Evidence status source linked
Cross-source check Single reviewed source
Source ClinicalTrials.gov A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers
Publisher ClinicalTrials.gov
Date Jul 9, 2026
Trust tier clinical-trials
License ClinicalTrials.gov public registry record